In vitro activity of novel 1,3-oxazole derivatives against human papillomavirus.

Authors

  • M. V. Kachaeva Department of Chemistry of Bioactive Nitrogen Containing Heterocyclic Bases, Institute of Bioorganic Chemistry and Petrochemistry, NAS of Ukraine, Kyiv, Ukraine
  • G. S. Pilyo Department of Chemistry of Bioactive Nitrogen Containing Heterocyclic Bases, Institute of Bioorganic Chemistry and Petrochemistry, NAS of Ukraine, Kyiv, Ukraine
  • A. M. Kornienko Department of Chemistry of Bioactive Nitrogen Containing Heterocyclic Bases, Institute of Bioorganic Chemistry and Petrochemistry, NAS of Ukraine, Kyiv, Ukraine
  • V. M. Prokopenko Department of Chemistry of Bioactive Nitrogen Containing Heterocyclic Bases, Institute of Bioorganic Chemistry and Petrochemistry, NAS of Ukraine, Kyiv, Ukraine
  • V. V. Zhirnov Department of Chemistry of Bioactive Nitrogen Containing Heterocyclic Bases, Institute of Bioorganic Chemistry and Petrochemistry, NAS of Ukraine, Kyiv, Ukraine
  • V. S. Brovarets Department of Chemistry of Bioactive Nitrogen Containing Heterocyclic Bases, Institute of Bioorganic Chemistry and Petrochemistry, NAS of Ukraine, Kyiv, Ukraine

Abstract

Chemotherapeutic approaches to the control of HPV (human papillomavirus) infection suffer from a lack of specificity. For most existing HPV inhibitors, the weak antiviral effects observed in cellular assays suggest that further improvements in selecting targets, in drug potency, and in bioavailability and cell uptake are required. Substituted 1,3-oxazoles can exert various biological effects and have significant antiviral activity.

The present study is an exploratory investigation of anti-HPV activity by novel 1,3-oxazole derivatives (1,3-oxazol sulfonamides and 5-amino-1,3-oxazole-4-carbonitriles) designed and synthesized in Kyiv, with all the cytotoxicity and efficacy tests performed in the the National Institute of Allergy and Infectious Diseases (USA).

Downloads

Issue

2018

Section

Medical and Farmaceutical Chemistry